Cambridge Investment Research Advisors, Inc. Cue Biopharma, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 20,000 shares of CUE stock, worth $20,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,000
Previous 22,200
9.91%
Holding current value
$20,000
Previous $28,000
46.43%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CUE
# of Institutions
52Shares Held
14.1MCall Options Held
14.4KPut Options Held
2.6K-
Bleichroeder LP New York, NY5MShares$5 Million1.28% of portfolio
-
Slate Path Capital LP New York, NY2.4MShares$2.4 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.03MShares$2.03 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$756,7360.0% of portfolio
-
Geode Capital Management, LLC Boston, MA509KShares$508,8270.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $35.4M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...